Published in Lab Business Week, September 25th, 2005
SV Life Sciences led the investment round together with Alta Partners and are joined by HealthCap, Red Abbey Venture Partners and the Maryland Venture Fund. Additional participants in the round include existing investors Esperance BioVentures, Astellas Ventures, Maryland TEDCO, and Townsend Capital.
"This financing brings together an international group of investors committed to advancing the company's lead product candidate, AT-1001, through proof-of-concept in humans," said Lutz Giebel, PhD, Venture Partner of SV Life Sciences. "The company has made outstanding...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.